Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype

Objective To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with polyangiitis (EGPA) with and without a vasculitic phenotype. Methods The MIRRA study (NCT02020889/GSK ID: 115921) included adults with relapsing/refractory EGPA and 4 or more weeks of stable oral glucocorticoids (O...

Повний опис

Бібліографічні деталі
Автори: Benjamin Terrier, David R.W. Jayne, Bernhard Hellmich, Jane H. Bentley, Jonathan Steinfeld, Steven W. Yancey, Namhee Kwon, Praveen Akuthota, Paneez Khoury, Lee Baylis, Michael E. Wechsler, the EGPA mepolizumab study team
Формат: Стаття
Мова:English
Опубліковано: Wiley 2023-07-01
Серія:ACR Open Rheumatology
Онлайн доступ:https://doi.org/10.1002/acr2.11571

Інтернет

https://doi.org/10.1002/acr2.11571

Схожі ресурси